Naivex 50mg (Dolutegravir)
Naivex tablets are containing a functioning substance known as Dolutegravir, which is an inhibitor of human immunodeficiency infection Integrase strand transmission. Naivex tablet is a physician endorsed drug, which is supported by FDA for the HIV-1 treatment.
DESCRIPTION
Naivex tablets are containing a functioning substance known as Dolutegravir, which is an inhibitor of human immunodeficiency infection Integrase strand transmission. Naivex tablet is a physician endorsed drug, which is supported by FDA for the HIV-1 treatment.
Dolutegravir isn't utilized all things considered; it might consolidate with another against retroviral solutions. Naivex tablets are not ready to cure the disease; just it might decrease the spreading and drains
INDICATION
Naivex and are hostile to retro viral medications, utilized as a part of the treatment of HIV-1 disease, to anticipate facilitate ailment AIDS. Naivex and are typically utilized as a part of mix, for removing better hostile to retro viral action. Naivex utilized as a part of adults and pediatric with body weight of no less than 30kg.
MECHANISM OF ACTION
Naivex (Dolutegravir) contains antagonistic to viral property against HIV compose I infection. Naivex is classified as an Integrase inhibitor, which can prepared to limit HIV cell improvement by interfering with Integrase definitive to the dynamic site and blockade of strands trade step happened. The viral DNA mix into have cells get stopped This trade method is responsible for HIV cell increment cycle. This prompts impediment of viral activity
ADME PROPERTIES
ABSORPTION
Maximum plasma concentration time of Dolutegravir is 2 to 3 hours The steady state level reaches within 5 days
DISTRIBUTION
Dolutegravir is highly bound to human plasma protein at 98.9%
METABOLISM
The metabolism of Dolutegravir is occurs through UGT1A1 with some additional contribution from CYP3A.
ELIMINATION
The Dolutegravir half life of is 14 hours. The major route of elimination is urine & as an unchanged form through feces.
DOSAGE MANAGEMENT
NAIVEX DOSAGE
In Naivex measurement considers, Creatinine freedom, urine glucose, urine protein esteem ought to be explored. Naivex containing 50mg of Dolutegravir.
DOSAGE RECOMMENDATION
The standard measurement of Naivex is one tablet of 50mg to be taken as a solitary dosage as orally. Naivex can be taken with or without food but probably taken with food to enhance exposure. In adults: INSTI (Integrase strand transfer inhibitor)
FOR NEW PATIENTS OR EXPERIENCED INSTI NEW OR VIROLOGICALLY RESTRAINED
The recommended dose of Naivex 50mg should be taken as once a day
FOR NEW OR EXPERIENCED INSTI NEW BY COMBINING WITH UGT1A OR CYP3A INDUCERS
The recommended dosage of Naivex is 50mg should be given as two times a day
FOR INSTI ALREADY TREATED WITH CERTAIN INSTI RELATED RESISTANCE ALTERNATIVES
The recommended dosage of Naivex is 50mg should be given as two times a day
IN PEDIATRIC
The recommended dosage of Naivex for 30 to less than 40kg patients: 35mg should be taken as a once a day For 40kg or greater patients: The prescribed dosage is 50mg once daily.
SIDE EFFECTS
UNDESIRABLE EFFECTS OF INSTGRA
For Naivex ; The adverse effects occur in this therapy; Immune reconstitution syndrome Liver toxicity Anaphylactic reactions
THE MOST COMMON SIDE EFFECTS LIKE
Insomnia Anxiety Depression Creatine kinase elevation Increase in lipase Neutrophils elevation
PRECAUTION
SAFETY PRECAUTIONS OF INSTGRA
Hypersensitivity reaction: This may occur due to contraindication Lack of virological response during drug interaction: The Resistance of Naivex may occur in some patients during concomitant use with some drugs. Immune reconstitution syndrome: Some immune restructuring ailment is occurred during the initial stage of anti-retro viral therapy Liver damage: Elevation of AST & ALT levels causing liver damage; to avoid this problem monitor the patients with frequent liver function test.
DRUG INTERACTION
Naivex combines with drugs excreted through OCT2 or MATE1 (dofetilide or metformin), causes elevation of plasma concentration of these drugs. Naivex combined with etravirine causes decrease in plasma concentration of Dolutegravir.
Naivex concurrently used with anti-mycobacterials, anti-convulsants or herbal products causes depletion in plasma concentration of Dolutegravir. Dolutegravir is a substrate of UGT1A3, UGT1A9, BCRP & P-gp transporters. Naivex combined with the drug which prohibits these enzymes or transporters cause, increasing the plasma concentration of Dolutegravir.
Naivex tablets is concomitant use with non-nucleoside reverse transcriptase inhibitors; causing depletion of effect of concentration of Naivex . If Naivex tablets is combines with protease inhibitor causes decreasing in plasma concentration of Dolutegravir.
CONTRAINDICATION
In Naivex causes some hypersensitivity reaction to the patients who are contraindicated to the component of Naivex tablet.
PREGNANCY
The pregnancy category of Dolutegravir is B Utilizing Naivex in pregnancy condition with alert, simply in the wake of knowing the hazard components to the hatchling of these items Most of the patients placental change happens, in such conditions discontinue the use of these compounds.
LACTATION
In HIV conditions, generally Breast feeding is not recommended, it may have chance to transfer virus from mother to fetus. Avoid using the drug during feeding.
PEDIATRIC
The potency of the Naivex should not be evaluated in the pediatric patients with the body weight of less than 25kg.
RENAL IMPAIRMENT
Dosage adjustment is not recommended for both severe renal & hepatic impaired patients.
STORAGE
Naivex container should be stored at 25°C, keep the container away from light, moisture & heat.
MISSED DOSE
Naivex , are anti-retroviral medicines, if missed dose occurred during the course of therapy, must be consult with medical practitioner and follow the instruction as per their advice. Or , the missed dose should be avoided and follow the regular schedule.
OVER DOSAGE
There are no specific antitoxin is given for over dosage of Naivex , because Dolutegravir is highly bound to human plasma protein.
Пока нет комментариев